Home

Editas Medicine, Inc. - Common Stock (EDIT)

1.7850
+0.0150 (0.85%)

Editas Medicine is a biotechnology company that focuses on developing transformative therapies based on the groundbreaking gene editing technology known as CRISPR

The company is dedicated to harnessing the power of this technology to correct genetic defects, treat serious diseases, and ultimately improve patient outcomes. Editas is engaged in advancing research and development initiatives aimed at addressing various genetic disorders, including inherited diseases and conditions that currently lack effective treatments, all while driving innovation in the field of genomic medicine. Through collaboration with leading scientists and institutions, Editas aims to bring its pioneering therapies from the lab to the clinic, making a meaningful impact in the lives of patients.

SummaryNewsPress ReleasesChartHistoricalFAQ
Peering Into Editas Medicine's Recent Short Interestbenzinga.com
Via Benzinga · February 25, 2025
What's going on in today's sessionchartmill.com
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · February 20, 2025
Top movers in Thursday's sessionchartmill.com
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · February 20, 2025
Stay updated with the stocks that are on the move in today's pre-market session.chartmill.com
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · February 20, 2025
12 Analysts Have This To Say About Editas Medicinebenzinga.com
Via Benzinga · December 11, 2024
Expert Outlook: Editas Medicine Through The Eyes Of 7 Analystsbenzinga.com
Via Benzinga · October 23, 2024
Where Editas Medicine Stands With Analystsbenzinga.com
Via Benzinga · September 17, 2024
Top movers analysis one hour before the close of the markets on 2025-02-19: top gainers and losers in today's session.chartmill.com
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Via Chartmill · February 19, 2025
Here are the top movers in Wednesday's session.chartmill.com
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · February 19, 2025
JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Cautionbenzinga.com
Editas Medicine pivots to in vivo gene editing, extends cash runway to 2027, but faces investor caution amid unclear proof-of-concept timelines.
Via Benzinga · December 17, 2024
Walmart To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Fridaybenzinga.com
Via Benzinga · December 13, 2024
Unveiling 5 Analyst Insights On Editas Medicinebenzinga.com
Via Benzinga · June 18, 2024
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Expertsbenzinga.com
Via Benzinga · May 30, 2024
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Fridaybenzinga.com
Via Benzinga · December 13, 2024
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026benzinga.com
Editas Medicine pivots to in vivo gene editing, extends cash runway to Q2 2027, and reduces its workforce by 65%. The company reports breakthroughs in HSC and liver editing.
Via Benzinga · December 13, 2024
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30talkmarkets.com
Via Talk Markets · November 30, 2024
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalystsbenzinga.com
Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13.
Via Benzinga · November 25, 2024
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.investors.com
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.
Via Investor's Business Daily · September 26, 2024
Looking for Stock Bargains With Room to Run? Try This.fool.com
Investing tips from Bill Mann, The Motley Fool's director of small-cap research.
Via The Motley Fool · September 11, 2024
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursdaybenzinga.com
Via Benzinga · August 8, 2024
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Editioninvestorplace.com
Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders.
Via InvestorPlace · July 17, 2024
3 Profitable CRISPR Stocks Earning Analysts’ Praiseinvestorplace.com
Revolutionary gene-editing technologies provide promise for investors seeking the most profitable CRISPR stocks today and in the future.
Via InvestorPlace · July 9, 2024
The 3 Best Gene Editing Stocks to Buy in July 2024investorplace.com
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks.
Via InvestorPlace · July 8, 2024
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Richinvestorplace.com
Gene editing is a game-changer, creating substantial opportunities for some of the leading gene editing stocks.
Via InvestorPlace · June 26, 2024
3 Gene Editing Stocks That Could Make Your Grandchildren Richinvestorplace.com
Explore gene-editing stocks with long-term growth potential, offering innovative solutions to previously untreatable conditions.
Via InvestorPlace · June 25, 2024